Table 2.
Global Incidence and Prevalence of NAFLD
| Author (year) | Country | Description of study | Diagnostic method | Incidence or prevalence of NAFLD (%) |
|---|---|---|---|---|
| Incidence | ||||
| Younossi et al. (2016)9 |
Asia and Israel | 5 Studies | Ultrasonography, computed tomography scan OR magnetic resonance spectroscopy OR blood testing | For Asia, 52.3 per 1,000 (95% CI, 28.31–96.77); Israel, 28.01 per 1,000 person-years (95% CI, 19.34–40.57) |
| Li et al. (2019)10 | Asia | 18 Studies | Ultrasonography, computed tomography scan OR magnetic resonance imaging/spectroscopy OR liver biopsy OR blood testing/predictive indices (fatty liver index or hepatic steatosis index) or ICD-9-CM codes | 50.9 per 1,000 person-years (95% CI, 44.8–57.4) |
| Allen et al. (2018)11 | USA | Community cohort study (n=3,869 subjects) |
ICD-9-CM codes | 329 per 100,000 person–years in 2014 |
| Prevalence | ||||
| Younossi et al. (2016)9 |
Africa, Asia, Europe, Middle East, North America, South America | 86 Studies included in meta-analysis from 22 countries, 1989-2015 (n=8,515,431) | Ultrasonography, computed tomography scan OR magnetic resonance imaging/spectroscopy | 25.2% (95% CI, 22.1–27.9) |
| Li et al. (2019)10 | Asia | 237 Observational studies included in meta-analysis 1999-2019 (n=13,044,518) | Ultrasonography, computed tomography scan OR magnetic resonance imaging/spectroscopy, serum based indicies, OR liver biopsy | 30.5% (95% CI, 29.3–30.9) |
| Kim et al. (2013)15 | USA | US national representative samples (n=11,154) | Ultrasonography | 34.0% 3.2% (advanced fibrosis) |
| Abeysekera et al. (2020)16 |
UK | UK Avon Longitudinal Study of Parents and Children (ALSPAC) cohort (n=4,021) | Transient elastography with controlled attenuation parameter (CAP) score | 20.7% (95% CI, 19.4–22.0) for steatosis 2.7% (95% CI, 2.2–3.2) for suspected fibrosis (F2-F4) |
NAFLD, nonalcoholic fatty liver disease; CI, confidence interval; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification.